Repligen Corporation (RGEN)
- Previous Close
123.26 - Open
124.06 - Bid 113.67 x 200
- Ask 126.76 x 700
- Day's Range
120.11 - 126.56 - 52 Week Range
102.97 - 182.52 - Volume
1,228,034 - Avg. Volume
849,820 - Market Cap (intraday)
7.107B - Beta (5Y Monthly) 1.21
- PE Ratio (TTM)
-- - EPS (TTM)
-0.43 - Earnings Date Jul 28, 2025 - Aug 1, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
183.12
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
www.repligen.com1,778
Full Time Employees
December 31
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: RGEN
View MorePerformance Overview: RGEN
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RGEN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RGEN
View MoreValuation Measures
Market Cap
7.11B
Enterprise Value
7.09B
Trailing P/E
--
Forward P/E
76.34
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.90
Price/Book (mrq)
3.58
Enterprise Value/Revenue
10.91
Enterprise Value/EBITDA
81.90
Financial Highlights
Profitability and Income Statement
Profit Margin
-3.53%
Return on Assets (ttm)
0.92%
Return on Equity (ttm)
-1.16%
Revenue (ttm)
650.43M
Net Income Avi to Common (ttm)
-22.98M
Diluted EPS (ttm)
-0.43
Balance Sheet and Cash Flow
Total Cash (mrq)
697.23M
Total Debt/Equity (mrq)
34.44%
Levered Free Cash Flow (ttm)
183.66M